ReviewMedicina (Kaunas, Lithuania)2021
Recent Updates in the Treatment of Erythema Multiforme.
Review in Medicina (Kaunas, Lithuania), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Photodistributed Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and proposal for a new diagnostic classification.European journal of medical research · 2023Pooled it
- Article
- Breaking the cycle: successful long-term remission of chronic erythema multiforme with rituximab therapy.Skin health and disease · 2026Article
- Lamotrigine-induced Stevens-Johnson syndrome in the setting of mitochondrial encephalomyopathy: A case report.Therapeutic advances in neurological disorders · 2026Article
- Successful management of recurrent erythema multiforme with upadacitinib: A case report.JAAD case reports · 2025Article
- Low-dose venlafaxine-induced erythema multiforme: a case report.Journal of medical case reports · 2025Article
- Erythema Multiforme Secondary to Mumps.The American journal of tropical medicine and hygiene · 2025Article
- Urticaria.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2024Review
- Repurposing Historic Drugs for Neutrophil-Mediated Inflammation in Skin Disorders.Biomolecules · 2024Review
- Article
- Oral Erythema Multiforme: A Case Report and Review of Diagnostic, Therapeutic and Prognostic Challenges.Cureus · 2024Article
- Recurrent erythema multiforme in the setting of COVID-19 infection and oral candidiasis: A case for dysregulation of the T helper 17/interleukin 17 axis.JAAD case reports · 2024Article
- Article
- The most common skin symptoms in young adults and adults related to SARS-CoV-2 virus infection.Archives of dermatological research · 2024Review
- Finger nodules with a papulovesicular hands and feet eruption: a complicated human Orf virus infection.BMC infectious diseases · 2024Article
- Toxic epidermal necrolysis after injection of sclerosing agent and medical adhesive into oesophageal variceal ligation in a patient with a malignant liver tumour: A case report.Experimental and therapeutic medicine · 2024Article
- Vaping as a Risk Factor for Oral Erythema Multiforme: A Case Report and Literature Review.International medical case reports journal · 2024Article
- Immunoglobulin-E (IgE) Screening for Detecting Mouthwash Allergic Reactions with Recurrent Oral Erythema Multiforme: A Case Report.International medical case reports journal · 2024Article
- Article
- Human Orf with Immune-Mediated Reactions: A Systematic Review.Microorganisms · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. EM can be confused with other more serious conditions like Stevens-Johnson syndrome (SJS); however, clinical research has provided significant evidence to classify EM and SJS as separate disorders. Treatment of EM is highly variable, depending on the etiology, the involvement of mucosal sites, and the chronicity (acute vs. recurring) of the disease. If the etiology or causal medication/infection is identified, then the medication is stopped and/or the infection is treated prior to initiating symptomatic treatment. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.